CervoMed CRVO
NASDAQ CRVO
$1.77 +0.40 (+29.20%)
At close: Nov 11, 2026 · 4:00 PM EST

CervoMed (CRVO) Gains from Sales and Divestitures (2014 - 2015)

Updated

CervoMed (CRVO) recorded Gains from Sales and Divestitures of -$51,782 in FY2021.

Analysis

CervoMed (CRVO) Gains from Sales and Divestitures (2014 - 2015) Analysis & Trends

Starting with FY2014, CervoMed's Gains from Sales and Divestitures history includes 4 years.

  • The FY2021 figure is the highest annual Gains from Sales and Divestitures since FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 CervoMed 20.73 Mn -57.60 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 48,151.00
Sep 30, 2015 -49,278.00
Jun 30, 2015 49,278.00
Sep 30, 2014 -6,056.00
Jun 30, 2014 6,056.00
API Access

CervoMed Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CRVO&period=max&api_key=YOUR_API_KEY